Investment Analysts’ Weekly Ratings Changes for Traws Pharma (TRAW)

Traws Pharma (NASDAQ: TRAW) recently received a number of ratings updates from brokerages and research firms:

• 6/15/2026 – Traws Pharma was downgraded by Citigroup Inc. to “neutral”.
• 6/15/2026 – Traws Pharma was downgraded by LADENBURG THALM/SH SH from “buy” to “neutral”.
• 6/13/2026 – Traws Pharma was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/30/2026 – Traws Pharma was downgraded by Wall Street Zen to “strong sell”.
• 5/29/2026 – Traws Pharma was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
• 5/20/2026 – Traws Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 5/15/2026 – Traws Pharma was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/1/2026 – Traws Pharma was upgraded by Weiss Ratings from “sell (d-)” to “sell (d+)”.

Insider Transactions at Traws Pharma

In related news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were acquired at an average cost of $1.67 per share, with a total value of $998,207.43. Following the completion of the acquisition, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.57% of the stock is currently owned by insiders.

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.